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A 23-year-old woman with an alveolar soft-part sarcoma of her calf with pulmonary metastases unresponsive to chemotherapy is
described. Interferon (IFN) alpha-2b induced an impressive tumour response still ongoing after IFN treatment had to be stopped
because of a psychosis. An explanation of this effect is still speculative.
British Journal of Cancer (2003) 89, 243–245. doi:10.1038/sj.bjc.6601074 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: alveolar soft-part sarcoma; interferon alpha-2b; antiangiogenic activity
                              
Alveolar soft-part sarcoma (ASPS), a rare soft tissue sarcoma in
young adults, preferentially presents as a quite large, painless
tumour mass in the lower extremities. The microscopic picture
shows an organoid nest-like arrangement of large polygonal cells,
surrounded by thin-walled vascular channels. Mitotic figures are
scarce. Central degeneration with loss of cohesion in the nests
often provides a pseudoalveolar pattern. The cells contain varying
amounts of glycogen and ‘diagnostic’ PAS-positive diastase-
resistant crystalline material. Frequently, numerous multiple
arteriovenous shunts are seen in the tumour (Enzinger and Weiss,
2001), across which sometimes a murmur can be heard (van Ruth
et al, 2002). The histogenesis is still unresolved. A skeletal muscle
origin of the tumour cells has been assumed, but recent studies
with application of more advanced techniques did not confirm this
concept (Gomez et al, 1999). Cytogenetic analysis revealed a clonal
translocation between chromosomes X and 17 (Joyama et al, 1999).
Unresectable disease or metastases at onset are present in about
35–50%, but usually metastases to lung, brains and bone appear
later. Alveolar soft-part sarcoma generally progresses slowly, with
a median survival of 48 months and an overall 5-year survival of
38% in young adults. The ultimate prognosis is still poor. There is
only a partial response on chemotherapy in various combinations,
in about 30% (Casanova et al, 2000; van Ruth et al, 2002).
We describe a 24-year-old woman with chemoresistant ASPS
showing a still ongoing good partial response to interferon (IFN)
alpha-2b.
CASE REPORT
A 24-year-old woman presented in June 2000 with a fast-growing,
tender swelling of her right calf without systemic complaints.
Magnetic resonance imaging (MRI) showed a tumour of the
gastrocnemius muscle around the right fibula of 5.58cm without
invasion of surrounding structures. Incision biopsy of the tumour
(July 2000) revealed the characteristic histological pattern of ASPS
with diastase-resistant PAS-positive accumulations of crystalline
material identified in the cytoplasm. The cells showed immunor-
eactivity for vimentin, desmin and for S-100 protein. Other muscle
markers (SMA, HHF-35), melanoma markers (HMB-45, KBA-62),
and epithelial markers (Lu-5, CAM 5.2) were negative. Isolated
limb perfusion was considered, but the thorax computed
tomography (CT) scan revealed multiple, pulmonary metastases
on both sides that were not resectable. Computed tomography
scans of abdomen and brain were normal.
RESULTS OF TREATMENT
After treatment with three courses of intensive chemotherapy
according to the SIOP-MTT-98 study for metastatic malignant soft
tissue sarcomas of childhood, the lung metastases (Figure 1A) and
primary tumour (Figure 2A) showed obvious progression. High-
dose chemotherapy followed by peripheral stem cell transplanta-
tion was considered too toxic. After three oral etoposide and three
topotecan courses, progression continued. In April 2001, treatment
with IFN alpha-2b (310
6IU s.c.day
1), was started, resulting in a
gradual softening of the primary tumour. After 3 months, the dose
was increased to 510
6IU s.c.day
1, and after a further 3 months,
a good partial regression of the pulmonary metastases (Figure 1B)
and tumour in the calf (Figure 2B) was confirmed. Two months
later (December 2001), IFN alpha-2b had to be discontinued
because the patient developed an acute psychotic syndrome.
Contrast-enhanced CT scan of the brain revealed no abnormalities.
After stopping IFN alpha-2b, she still remains in a good partial
remission and has almost completely recovered from her psychosis.
DISCUSSION
Primary conservative surgery is the mainstay of therapy of ASPS,
eventually preceded by isolated limb perfusion in case of
questionable resectability or followed by local radiation. The ASPS
of the patient in this case report was clearly progressive during a 4
months lasting treatment with three combination chemotherapy
schemes and two periods of single-agent treatment. In an ultimate
effort to inhibit the progressive growth of this well-vascularised
tumour, treatment with the relatively weak and nonspecific
angiogenesis inhibitor IFN alpha-2b was initiated. After a 6 months
lasting period of stable disease, this treatment resulted in an
impressive partial regression of primary tumour and lung Received 12 February 2003; accepted 15 April 2003
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acute psychotic syndrome, interpreted as side effects of the
interferon, the remission now lasts for 14 months, while the patient
has recovered from her psychosis. A comparable observation has
recently been described in an 8-year-old boy (Kuriyama et al, 2001).
The explanation for regression of ASPS after IFN alpha treatment
is still speculative. Growth inhibition may be mediated by IFN alpha-
receptors shown to be present in most solid tumours in childhood
(Rosolen et al, 1997). However, information about expression of this
receptor in ASPS is lacking. Otherwise, the efficacy of IFN alpha may
be attributed to growth inhibition of microvascular endothelial cells
as described in haemangiomas of infancy, by inhibiting basic
fibroblast growth factor (bFGF) overproduction by tumour cells
(Folkman, 1989) or by modulation of the immune effector cells.
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Figure 1 Axial CT section after three courses of chemotherapy (A)
reveals multiple nodules of variable size consistent with metastases with a
predominantly subpleural localisation. After IFN alpha-2b therapy, almost
complete disappearance of the multiple subpleural metastases is shown
(B).
Figure 2 Fat-suppressed T2-weighted axial MR image after three
courses of chemotherapy (A). A relatively well-defined mass of
heterogeneous high signal intensity is shown in the right calf. Compared
with the prechemotherapy MR examination (not shown), a small increase
in tumour volume was noticed. After treatment with IFN alpha-2b, there is
an obvious decrease of the tumour in the right calf with an overall decrease
in signal intensity and a focal remnant area of high signal intensity on the
lateral side (B).
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